Conference Call and Webcast at 8:30 AM Eastern Time
NEW
YORK, July 30, 2024 /PRNewswire/
-- PAVmed Inc. (Nasdaq: PAVM, PAVMZ)
("PAVmed" or the "Company"), a diversified commercial-stage medical
technology company, operating in the medical device, diagnostics,
and digital health sectors, today announced that it will host a
business update conference call and webcast on Tuesday, August 13, 2024, at 8:30 AM ET. During the call, Lishan Aklog, M.D., PAVmed's Chairman and Chief
Executive Officer, will provide a business update including an
overview of the Company's operations and growth strategy. In
addition, Dennis McGrath,
PAVmed's President and Chief Financial Officer, will discuss the
Company's second quarter 2024 financial results.
The webcast will be available at the investor
relations section of the Company's website at pavmed.com.
Alternatively, to access the conference call by telephone,
U.S.-based callers should dial 1-800-836-8184 and international
listeners should dial 1-646-357-8785. All listeners should provide
the operator with the conference call name "PAVmed Business Update"
to join.
Following the conclusion of the conference call, a replay will
be available for 30 days on the investor relations section of the
Company's website at pavmed.com.
About PAVmed
PAVmed Inc. is a diversified
commercial-stage medical technology company operating in the
medical device, diagnostics, and digital health sectors. Its
subsidiary, Lucid Diagnostics (Nasdaq: LUCD), is a
commercial-stage cancer prevention medical diagnostics company that
markets the EsoGuard® Esophageal DNA Test and
EsoCheck® Esophageal Cell Collection Device—the
first and only commercial tools for widespread early detection of
esophageal precancer to mitigate the risks of esophageal cancer
deaths. Its other main subsidiary, Veris Health, is focused on
commercialization of its digital cancer care platform with
physiologic data collection, symptom reporting and telehealth
functions, designed to improve personalized cancer care through
remote patient monitoring. Veris has also been developing an
implantable physiologic monitor containing biologic sensors capable
of generating continuous data on key physiologic parameters known
to predict adverse outcomes in cancer patients undergoing
treatment.
For more and for more information about PAVmed, please
visit pavmed.com.
For more information about Lucid Diagnostics, please
visit luciddx.com.
For more information about Veris Health, please
visit verishealth.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/pavmed-to-hold-a-business-update-conference-call-and-webcast-on-august-13-2024-302208065.html
SOURCE PAVmed Inc.